Merck KGaA says profit could slip as fertility treatments shunned

FRANKFURT (Reuters) - Merck KGaA said a slight decline in operating earnings was on the cards this year as the coronavirus pandemic weighs on demand for chemicals in TV screens and is putting couples off seeking the German group's fertility treatments.Earnings before interest, taxes, depreciation and amortisation (EBITDA), adjusted for one-off items, would likely be between 4.35 billion euros ($4.70 billion) and 4.85 billion euros, compared with 4.39 billion last year, it said on..